| Literature DB >> 27225279 |
Francesco Saccà1, Giorgia Puorro2, Angela Marsili2, Chiara Pane2, Cinzia Valeria Russo2, Roberta Lanzillo2, Anna de Rosa2, Antonio Cittadini3, Giuseppe De Angelis4, Vincenzo Brescia Morra2.
Abstract
We investigated patients who showed a second-degree atrioventricular block (S-AVB) after the first fingolimod administration. We observed six patients with S-AVB, three Mobitz type I, and three type II. Monitoring continued on the second day for all patients. Three patients showed persistence of the S-AVB, with resolution on the second or third day. One patient had a persistent S-AVB up to the fourth day when fingolimod was discontinued. We conclude that Mobitz type II S-AVB is possible during fingolimod therapy. Patients with S-AVB could be monitored until resolution of the S-AVBs, as these may persist several days after the first fingolimod administration.Entities:
Keywords: Atrioventricular block; Cardiac safety; Fingolimod; Mobitz type II; Multiple sclerosis; Relapsing; Tolerability; Treatment
Mesh:
Substances:
Year: 2016 PMID: 27225279 DOI: 10.1007/s10072-016-2621-y
Source DB: PubMed Journal: Neurol Sci ISSN: 1590-1874 Impact factor: 3.307